Medtech firms prioritize process automation for clinical trial collaboration.
ByAinvest
Wednesday, Aug 13, 2025 6:49 am ET1min read
VEEV--
The report underscores the significant challenges faced by medtech companies, including on-time data entry and data quality, document and data exchange, and monitoring and compliance. However, only 14% of medtechs with revenue over $1 billion and 24% with revenue under $1 billion have site collaboration tools in place, indicating a gap in the industry's efforts to improve trial efficiency and expedite study timelines [1].
Manual processes and regulatory compliance are cited as major hurdles, increasing operational costs and causing delays. To mitigate these risks, 58% of medtechs plan to prioritize data collection and cleaning in the next year. Additionally, nearly three-quarters (72%) of medtech organizations are planning to invest in AI and ML infrastructure to standardize data and make it AI-ready [1].
The study also highlights the importance of technology in simplifying and standardizing clinical workflows, enabling more effective collaboration with research sites, and speeding up trials. This shift towards technological solutions is driven by the need to balance economic pressures and new regulations, ensuring data integrity, operational efficiency, and connected processes across stakeholders [1].
References:
[1] https://www.prnewswire.com/news-releases/research-shows-medtechs-prioritizing-site-collaboration-and-data-quality-302527421.html
Veeva Systems has announced the results of its 2025 Veeva MedTech Clinical Benchmark study, which shows that clinical teams in the medical technology sector prioritize reducing manual processes (68%), improving study quality (56%), and gaining better visibility and control (55%) to streamline workflows, work more efficiently with sites, and speed up trials. The study highlights the potential of technology to simplify and standardize clinical trial workflows, improve collaboration, and accelerate research.
Veeva Systems has released the findings of its 2025 Veeva MedTech Clinical Benchmark, highlighting key priorities for clinical teams in the medical technology sector. The study, which surveyed over 100 clinical professionals, reveals that reducing manual processes (68%), improving study quality (56%), and enhancing visibility and control (55%) are top priorities to streamline workflows, improve collaboration, and accelerate research [1].The report underscores the significant challenges faced by medtech companies, including on-time data entry and data quality, document and data exchange, and monitoring and compliance. However, only 14% of medtechs with revenue over $1 billion and 24% with revenue under $1 billion have site collaboration tools in place, indicating a gap in the industry's efforts to improve trial efficiency and expedite study timelines [1].
Manual processes and regulatory compliance are cited as major hurdles, increasing operational costs and causing delays. To mitigate these risks, 58% of medtechs plan to prioritize data collection and cleaning in the next year. Additionally, nearly three-quarters (72%) of medtech organizations are planning to invest in AI and ML infrastructure to standardize data and make it AI-ready [1].
The study also highlights the importance of technology in simplifying and standardizing clinical workflows, enabling more effective collaboration with research sites, and speeding up trials. This shift towards technological solutions is driven by the need to balance economic pressures and new regulations, ensuring data integrity, operational efficiency, and connected processes across stakeholders [1].
References:
[1] https://www.prnewswire.com/news-releases/research-shows-medtechs-prioritizing-site-collaboration-and-data-quality-302527421.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet